Literature DB >> 30093418

P450-Humanized and Human Liver Chimeric Mouse Models for Studying Xenobiotic Metabolism and Toxicity.

Karl-Dimiter Bissig1, Weiguo Han2, Mercedes Barzi2, Nataliia Kovalchuk2, Liang Ding2, Xiaoyu Fan2, Francis P Pankowicz2, Qing-Yu Zhang2, Xinxin Ding1.   

Abstract

Preclinical evaluation of drug candidates in experimental animal models is an essential step in drug development. Humanized mouse models have emerged as a promising alternative to traditional animal models. The purpose of this mini-review is to provide a brief survey of currently available mouse models for studying human xenobiotic metabolism. Here, we describe both genetic humanization and human liver chimeric mouse models, focusing on the advantages and limitations while outlining their key features and applications. Although this field of biomedical science is relatively young, these humanized mouse models have the potential to transform preclinical drug testing and eventually lead to a more cost-effective and rapid development of new therapies.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30093418      PMCID: PMC6199624          DOI: 10.1124/dmd.118.083303

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  164 in total

1.  Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling.

Authors:  Masahiro Utoh; Hiroshi Suemizu; Marina Mitsui; Mirai Kawano; Akiko Toda; Shotaro Uehara; Yasuhiro Uno; Makiko Shimizu; Erika Sasaki; Hiroshi Yamazaki
Journal:  Xenobiotica       Date:  2016-02-25       Impact factor: 1.908

2.  Prediction of human metabolism of the sedative-hypnotic zaleplon using chimeric mice transplanted with human hepatocytes.

Authors:  Chiaki Tanoue; Kazumi Sugihara; Naoto Uramaru; Yoshitaka Tayama; Yoko Watanabe; Toru Horie; Shigeru Ohta; Shigeyuki Kitamura
Journal:  Xenobiotica       Date:  2013-05-08       Impact factor: 1.908

Review 3.  Chimeric mice transplanted with human hepatocytes as a model for prediction of human drug metabolism and pharmacokinetics.

Authors:  Seigo Sanoh; Shigeru Ohta
Journal:  Biopharm Drug Dispos       Date:  2013-10-29       Impact factor: 1.627

4.  Human CYP2D6 and mouse CYP2Ds: organ distribution in a humanized mouse model.

Authors:  Sharon L Miksys; Connie Cheung; Frank J Gonzalez; Rachel F Tyndale
Journal:  Drug Metab Dispos       Date:  2005-07-20       Impact factor: 3.922

5.  Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice.

Authors:  Melanie A Felmlee; Hoi-Kei Lon; Frank J Gonzalez; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2007-11-29       Impact factor: 3.922

6.  The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model.

Authors:  Angelica Butura; Kerstin Nilsson; Kengathevy Morgan; Timothy R Morgan; Samuel W French; Inger Johansson; Ina Schuppe-Koistinen; Magnus Ingelman-Sundberg
Journal:  J Hepatol       Date:  2008-12-25       Impact factor: 25.083

7.  Simulation of human plasma concentration-time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling.

Authors:  Hidetaka Kamimura; Satoshi Ito; Hiroyuki Chijiwa; Takeshi Okuzono; Tomohiro Ishiguro; Yosuke Yamamoto; Sho Nishinoaki; Shin-Ichi Ninomiya; Marina Mitsui; Amit S Kalgutkar; Hiroshi Yamazaki; Hiroshi Suemizu
Journal:  Xenobiotica       Date:  2016-07-07       Impact factor: 1.908

8.  Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

Authors:  R McKenzie; M W Fried; R Sallie; H Conjeevaram; A M Di Bisceglie; Y Park; B Savarese; D Kleiner; M Tsokos; C Luciano
Journal:  N Engl J Med       Date:  1995-10-26       Impact factor: 91.245

9.  Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy.

Authors:  A Kenneth MacLeod; Jeffrey T-J Huang; Lesley A McLaughlin; Colin J Henderson; C Roland Wolf
Journal:  Clin Cancer Res       Date:  2018-02-06       Impact factor: 12.531

10.  Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model.

Authors:  Yasuhiro Kazuki; Masaharu Akita; Kaoru Kobayashi; Mitsuhiko Osaki; Daisuke Satoh; Ryo Ohta; Satoshi Abe; Shoko Takehara; Kanako Kazuki; Hiroshi Yamazaki; Tetsuya Kamataki; Mitsuo Oshimura
Journal:  Sci Rep       Date:  2016-02-23       Impact factor: 4.379

View more
  12 in total

Review 1.  Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.

Authors:  Antonio Segovia-Zafra; Daniel E Di Zeo-Sánchez; Carlos López-Gómez; Zeus Pérez-Valdés; Eduardo García-Fuentes; Raúl J Andrade; M Isabel Lucena; Marina Villanueva-Paz
Journal:  Acta Pharm Sin B       Date:  2021-11-18       Impact factor: 11.413

Review 2.  Contribution of Humanized Liver Chimeric Mice to the Study of Human Hepatic Drug Transporters: State of the Art and Perspectives.

Authors:  Anna Zerdoug; Marc Le Vée; Shotaro Uehara; Béatrice Lopez; Christophe Chesné; Hiroshi Suemizu; Olivier Fardel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-07-06       Impact factor: 2.569

Review 3.  Liver-humanized mice: A translational strategy to study metabolic disorders.

Authors:  Yonghong Luo; Haocheng Lu; Daoquan Peng; Xiangbo Ruan; Yuqing Eugene Chen; Yanhong Guo
Journal:  J Cell Physiol       Date:  2021-10-18       Impact factor: 6.513

Review 4.  Use of Zebrafish in Drug Discovery Toxicology.

Authors:  Steven Cassar; Isaac Adatto; Jennifer L Freeman; Joshua T Gamse; Iñaki Iturria; Christian Lawrence; Arantza Muriana; Randall T Peterson; Steven Van Cruchten; Leonard I Zon
Journal:  Chem Res Toxicol       Date:  2019-11-16       Impact factor: 3.739

Review 5.  PXR-mediated idiosyncratic drug-induced liver injury: mechanistic insights and targeting approaches.

Authors:  Jingheng Wang; Monicah Bwayi; Rebecca R Florke Gee; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-06-16       Impact factor: 4.481

Review 6.  Innovations, challenges, and minimal information for standardization of humanized mice.

Authors:  Renata Stripecke; Christian Münz; Jan Jacob Schuringa; Karl-Dimiter Bissig; Brian Soper; Terrence Meeham; Leonard Shultz; Li-Chin Yao; James P Di Santo; Michael Brehm; Estefania Rodriguez; Anja Kathrin Wege; Dominique Bonnet; Silvia Guionaud; Kristina E Howard; Scott Kitchen; Florian Klein; Kourosh Saeb-Parsy; Johannes Sam; Amar Deep Sharma; Andreas Trumpp; Livio Trusolino; Carol Bult
Journal:  EMBO Mol Med       Date:  2020-06-24       Impact factor: 12.137

7.  An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials.

Authors:  C J Henderson; Y Kapelyukh; N Scheer; A Rode; A W McLaren; A K MacLeod; D Lin; J Wright; L A Stanley; C R Wolf
Journal:  Drug Metab Dispos       Date:  2019-03-25       Impact factor: 3.922

Review 8.  Using CRISPR/Cas9 to model human liver disease.

Authors:  Michele Alves-Bezerra; Nika Furey; Collin G Johnson; Karl-Dimiter Bissig
Journal:  JHEP Rep       Date:  2019-10-25

9.  Sexual Dimorphism in Hepatocyte Xenograft Models.

Authors:  Gulce Sari; Gertine W van Oord; Martijn D B van de Garde; Jolanda J C Voermans; Andre Boonstra; Thomas Vanwolleghem
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

Review 10.  Role of Endocrine-Disrupting Chemicals in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: A Comprehensive Review.

Authors:  Raquel Cano; José L Pérez; Lissé Angarita Dávila; Ángel Ortega; Yosselin Gómez; Nereida Josefina Valero-Cedeño; Heliana Parra; Alexander Manzano; Teresa Isabel Véliz Castro; María P Díaz Albornoz; Gabriel Cano; Joselyn Rojas-Quintero; Maricarmen Chacín; Valmore Bermúdez
Journal:  Int J Mol Sci       Date:  2021-05-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.